The possibility of early detection of atherosclerotic vascular lesions in rheumatic diseases

   Identification of subclinical lesions of the heart and blood vessels in patients with rheumatic diseases (RD), as well as the comparison of subclinical markers of cardiovascular lesions in patients with RD and RD patients without having one of the risk factors for cardiovascular disease. Surveyed 56 patients (15 men and 41 female) at the age of 45.2 ± 13.42 years with different rheumatic diseases. For the comparison group surveyed residents of one of the districts of Saint Petersburg (50 people). All patients have been conducted questioning, characterizes lifestyle, risk factors, comorbidity and drug therapy. Anthropometry were measured in weight, height with a calculation of body mass index, waist circumference, hip circumference. Endothelial dysfunction study conducted on the Endo Pat 2000 (company “Itamar Medical Ltd, Israel): reactive hyperemia index (RHI) and augmentation index (AI). Dysfunction of the endothelium have registered a value of RHI < 1.64. Echocardiography and ultrasonography of carotid arteries with the assessment of the thickness of the thickness intima-media (TIM) conducted by Vivid 7 high resolution sensor 7 MHz. Central pressure values determined on device SphygmoCor (Australia) by applanation tonometry. The speed of pulse wave (SPW) carotid artery, femoral artery measured the sphygmography method on the device Sphygmo-Cor PWX. On an empty stomach identified glucose and lipid levels (Hitachi-902). Average levels of cholesterol, triglycerides, SAD/DAD, BMI in groups not significantly different. Identify correlation titer of antinuclear factor with RHI, p = 0.53; AI (EndoPat), p = 0.47; PP, p = – 0.43. Among persons 1 group (systemic sclerosis) frequently detected RHI < 1,64 and SPW > 9.6 m/s compared to the 2nd and 3rd groups of patients with RD. We have identified correlate titer of antinuclear factor, reactive hyperemia index (RHI), augmentation index (AI, EndoPat), the central pulse pressure (PP) show integration structures of the cardiovascular system in the pathological process in RD, including asymptomatic from the system.

1. Баженов А. Н. Внезапная сердечная смерть при системных ревматических заболеваниях / А. Н. Баженов, О. П. Баженова // Бюл. Федерального Центра сердца, крови и эндокринологии им. В. А. Алмазова / А. Н. Баженов, О. П. Баженова. – 2012. – № 2. – С. 21–27.

2. Grover S., Sinha R. P., Singh U. et al. Subclinical atherosclerosis in rheumatoid arthritis in India // J. Rheumatol. 2006. Vol. 33, N 2. P. 201–203.

3. Bruce I. N. “Not only...but also”: factors that contribute to accelerated atherosclerosis and premature coronary heart disease in systemic lupus erythematosus // Rheumatology (Oxford). 2005. Vol. 44, N 12. P. 1492–1502.

4. Ahmad Y., Shelmerdine J., Bodill H. et al. Subclinical atherosclerosis in systemic lupus erythematosus (SLE): the relative contribution of classic risk factors and the lupus phenotype // Rheumatology (Oxford). 2007. Vol. 46, N 6. P. 983–988.

5. Carotti M., Salaffi F., Mangiacotti M. et al. Atherosclerosis in rheumatoid arthritis: the role of high-resolution B mode ultrasound in the measurement of the arterial intima-media thickness // Reumatismo. 2007. Vol. 59, N 1. P. 38–49.

6. Colombo B. M., Murdaca G., Caiti M. et al. Intimamedia thickness: a marker of accelerated atherosclerosis in women with systemic lupus erythematosus // Ann. N. Y. Acad. Sci. 2007. N 1108. P. 121–126.

7. Foster W., Carruthers D., Lip G. Y., Blann A. D. Inflammation and Microvascular and Macrovascular Endothelial Dysfunction in Rheumatoid Arthritis: Effect of Treatment // J. Rheumatol. 2010. Vol. 37, N 4. P. 711–716.

8. Bergholm R., Leirisalo-Repo M., Vehkavaara S., et al. Impaired responsiveness to NO in newly diagnosed patients with rheumatoid arthritis // Arteriol. Thromb. Vasc. Biol. 2002. Vol. 22. P. 1637–1641.

9. Vaudo G., Marchesi S., Gerli R. et al. Endothelial dysfunction in young patients with rheumatoid arthritis and low disease activity // Ann. Rheum. Dis. 2004. Vol. 63. P. 31–35.

10. Hansel S., Lasing G., Pistrosch F., Passauer J. Endothelial dysfunction in young patients with long–term rheumatoid arthritis and low disease activity // Atherosclerosis. 2003. Vol. 17. P. 177–180.

11. Gonzalez-Juanatey C., Testa A., Garcia-Castelo A. et al. HLA–DRB1 status affects endothelial function in treated patients with rheumatoid arthritis // Am. J. Med. 2003. Vol. 114. P. 647–652.

12. Мясоедова Е. Е. Структурно-функциональные особенности миокарда левого желудочка и эндотелиальная дисфункция при ревматоидном артрите в зависимости от наличия артериальной гипертонии / Е. Е. Мясоедова [и др.] // Науч.-практ. ревматология. – 2007. – № 3. – С. 15–20.

13. Хусаинова Д. К. Эндотелиальная дисфункция и артериальная гипертензия у больных ревматоидным артритом / Д. К. Хусаинова [и др.] // Науч.-практ. ревматология. – 2006. – № 3. – С. 27–32.

14. De Leeuw K., Freire B., Smit A. J. et al. Traditional and non-traditional risk factors contribute to the development of accelerated atherosclerosis in patients with systemic lupus erythematosus // Lupus. 2006. Vol. 15, N 10. P. 675–682.

15. Dessein P. H., Joffe B. I., Singh S. Biomarkers of endothelial dysfunction, cardiovascular risk factors and atherosclerosis in rheumatoid arthritis // Arthritis Res. Ther. 2005. Vol. 7, N 3. P. 634–643.

16. Frostegard J. SLE, atherosclerosis and cardiovascular disease // J. Intern. Med. 2005. Vol. 257, N 6. P. 485–495.

17. Maksimowicz-McKinnon K., Magder L. S., Petri M. Predictors of carotid atherosclerosis in systemic lupus erythematosus // J. Rheumatol. 2006. Vol. 33, N 12. P. 2458–2463.

18. Klocke R., Cockcroft J. R., Taylor G. J. et al. Arterial stiffness and central blood pressure, as determined by pulse wave analysis, in rheumatoid arthritis // Ann. Rheum. Dis. 2003. Vol. 62. P. 414–418.

19. Van Dorum S., McColl G., Wicks I. P. Atorvastatin reduces arterial stiffness in patients with rheumatoid arthritis // Ann. Rheum. Dis. 2004. Vol. 63. P. 1571–1575.

20. Bacon P. A., Stevens R. J., Carruthers D. M., Young S. P., Kitas G. D. Accelerated atherogenesis in auto immune rheumatic diseases // Autoimmun Rev. 2002. Vol. 1, N 6. P. 338–347.

21. Azevedo V. F., Pecoits-Filho R. Atherosclerosis and endothelial dysfunction in patients with ankylosing spondylitis // Rheumatol Int. 2010. Vol. 30, N 11. P. 1411–1416.

22. Westerweel P. E., Verhaar M. C. Endothelial progenitor cell dysfunction in rheumatic disease // Nat. Rev. Rheumatol. 2009. Vol. 5, N 6. P. 332–340.

23. Buckley C. D., Rainger G. E., Nash G. B., Raza K. Endothelial cells, fibroblasts and vasculitis // Rheumatology (Oxford). 2005. Vol. 44, N 7. P. 860–863.

24. Szekanecz Z., Kerekes G., Soltész P. Vascular effects of biologic agents in RA and spondyloarthropathies // Nat. Rev. Rheumatol. 2009. Vol. 5, N 12. P. 677–684.

25. Van Doornum S., McCo G., Jenkins A., Green D. J., Wicks I. P. Screening for atherosclerosis in patients with rheumatoid arthritis // Arthritis Rheum. 2003. Vol. 48. P. 72–80.

26. Hurlimann D., Forster A., Noll G. et al. Antitumor necrosis factor–alpha treatment improves endothelial function in patients with rheumatoid arthritis // Circulation. 2002. Vol. 106. P. 2184–2187.

27. Gonzalez-Juanatey C., Testa A., Garcia-Castelo A. et al. Active but transient imorovement of endothelial function in rheumatoid arthritis patients undergoing long–term treatment with anti–tumor necrosis factor alpha antibody // Arthritis Care & Res. 2004. Vol. 51. P. 447–450.

28. Wong M., Toh L., Wilson A. et al. Reduced arterial elasticity in rheumatoid arthritis and the relationship to vascular disease risk factors and inflammation // Arthritis Rheum. 2003. Vol. 48. P. 81–89.

29. Fischer-Betz R., Beer S., Schneider M. [Accelerated atherosclerosis in rheumatic systemic diseases as an example of systemic lupus erythematosus-what is the consequence?] // Z. Rheumatol. 2005. Vol. 64, N 4. P. 229–238.

30. Ильина А. Е. Атеросклеротическое поражение сосудов при системной красной волчанке у мужчин: связь с концентрацией C-реактивного белка / А. Е. Ильина [и др.] // Терапевт. арх. – 2005. – № 6. – С. 13–16.

31. Abou-Raya A., Abou-Raya S. Inflammation: a pivotal link between autoimmune diseases and atherosclerosis // Autoimmun. Rev. 2006. Vol. 5, N 5. P. 331–337.

32. Chung C. P., Avalos I., Raggi P., Stein C. M. Atherosclerosis and inflammation: insights from rheumatoid arthritis // Clin. Rheumatol. 2007. Vol. 26, N 8. P. 1228–1233.

33. De Groot E., Hovingh K., Wiegman A. et al. Measurement of arterial wall thickness as a surrogate marker for atherosclerosis // Circulation. 2004. Vol. 109 (Suppl III); P. III-33–III-38.

34. Del Rincon I., Williams K., Stern M. P. et al. Association between carotid atherosclerosis and markers of inflammation in rheumatoid arthritis patients and healthy subjects // Arthritis Rheum. 2003. Vol. 48. P. 1833–1840.

35. Park Y.-B., Ahn C.-W., Choi H. K. et al. Atherosclerosis in rheumatoid arthritis. Morphologic evidence obtained by carotid ultrasound // Arthritis Rheum. 2002. Vol. 46. P. 1714–1719.

36. Kumeda Y., Inaba M., Goto H. et al. Increased thickness of the arterial intima–medis detected by ultrasonography in patients with rheumatoid arthritis // Arthritis Rheum. 2002. Vol. 46. P. 1489–1497.

37. Johsson S. W., Backman C., Johnson O., Karp K. et al. Increased prevalence of atherosclerosis in patients with medium term rheumatoid arthritis // J. Rheumatology. 2001. Vol. 28. P. 2597–2602.

38. Nagata-Sakurai M., Inaba M., Goto H. et al. Inflammation and bone resorbtion as independent factors of accelerated arterial wall thicening in patients with rheumatoid arthritis // Arthritis Rheum. 2003. Vol. 48. P. 3061–3067.

39. Alkaabi J. K., Ho M., Levinson R. et al. Rheumatoid arthritis and macrovascular disease // Rheumatology. 2003. Vol. 42. P. 292–297.

40. Tyrrell P. N., Beyene J., Feldman B. M., McCrindle B. W., Silverman E. D., Bradley T. J. Rheumatic disease and carotid intima-media thickness: a systematic review and meta-analysis // Arterioscler. Thromb. Vasc. Biol. 2010. Vol. 30, N 5. P. 1014–1026.

41. Gasparyan A. Y., Stavropoulos-Kalinoglou A., Mikhailidis D. P., Toms T. E., Douglas K. M., Kitas G. D. The rationale for comparative studies of accelerated atherosclerosis in rheumatic diseases // Curr. Vasc. Pharmacol. 2010. Vol. 8, N 4. P. 437–449.

42. Bruzzese V., Marrese C., Zullo A., Hassan C., Ridola L., Izzo A., Riccioni C. Carotid artery intima-media thickness in patients with autoimmune connective tissue diseases: a case-control study // Intern. Emerg. Med. 2011. Vol. 28. [Epub ahead of print].

43. Soltész P., Kerekes G., Dér H., Szücs G., Szántó S., Kiss E., Bodolay E., Zeher M., Timár O., Szodoray P., Szegedi G., Szekanecz Z. Comparative assessment of vascular function in autoimmune rheumatic diseases: considerations of prevention and treatment // Autoimmun. Rev. 2011. Vol. 10, N 7. P. 416–425.

44. Sarzi-Puttini P., Atzeni F., Gerli R., Bartoloni E., Doria A., Barskova T., Matucci-Cerinic M., Sitia S., Tomasoni L., Turiel M. Cardiac involvement in systemic rheumatic diseases: An update // Autoimmun Rev. 2010. Vol. 9, N 12. P. 849–852.